Recurrence-Free Survival Rates after External-Beam Radiotherapy for Patients with Clinical T1-T3 Prostate Carcinoma in the Prostate-Specific Antigen Era: What Should We Expect?

Cancer

Volumn 100, Issue 6, 2004, Pages 1283-1292

  Khuntia, Deepak ^a   Reddy, Chandana A ^a   Mahadevan, Arul ^a   Klein, Eric A ^a   Kupelian, Patrick A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Conformal radiotherapy; Intensity modulated radiotherapy; Prostate carcinoma; Prostate specific antigen; Risk group

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RACE; RADIATION BEAM; RADIATION DOSE; RISK; SCORING SYSTEM; STANDARD; TREATMENT FAILURE;

ADULT; AGED; ANDROGEN ANTAGONISTS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RISK FACTORS; SURVIVAL RATE;

EID: 1542284094     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20093     Document Type: Article

References (24)

1. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;46:567-574.
2. Mohan DS, Kupelian PA, Willoughby TR. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. Int J Radiat Oncol Biol Phys. 2000;46:575-580.
3. Pollack A, Zagars G, Starkshall G, et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys. 1996;34:555-564.
4. Kupelian PA, Willoughby TR. Short-course, intensity-modulated radiotherapy for localized prostate cancer. Cancer J. 2001;7:421-426.
5. Katcher J, Kupelian PA, Zippe C, Klein EA, Sohn JW. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 1997;37:871-876.
6. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
7. Davies-Johns T, Reddy C, Kupelian P. Localized prostate cancer treated with radiotherapy: who benefits from hormonal therapy? Int J Radiat Oncol Biol Phys. 2000;48(Suppl 1):170.
8. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
9. Zelefsky MJ, Fuks Z, Leibel SA. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol. 2002; 12:229-237.
10. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 2000;48:507-512.
11. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson Phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
12. Pinover WH, Hanlon AL, Horwitz EM, Hanks GE. Defining the appropriate radiation dose for pretreatment PSA ≥ 10 ng/mL prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 47:649-654.
13. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology. 2000;55:85-90.
14. Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol. 1998;8:107-114.
15. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116.
16. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8 -12 years' follow-up. Int J Radiat Oncol Biol Phys. 2002;54:427-435.
17. Hurwitz MD, Schnieder L, Manola J, Beard CJ, Kaplan ID, D'Amico AV. Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. Int J Radiat Oncol Biol Phys. 2002;53:1106-1110.
18. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:904-912.
19. Kupelian PA, Reddy CA, Carlson TP, Willoughby TR. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume? Cancer J. 2002;8:62-66.
20. Horwitz EM. Conformal radiotherapy with dose escalation appears safe and effective in localised prostate cancer. Cancer Treat Rev. 2003;29:219-221.
21. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280-1283.
22. Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys. 2003;56:1241-1247.
23. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17:3167-3172.
24. Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys. 2003;57:629-634.